312 related articles for article (PubMed ID: 7381862)
1. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
[TBL] [Abstract][Full Text] [Related]
2. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
[TBL] [Abstract][Full Text] [Related]
3. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine oxidation in an Australian population.
Peart GF; Boutagy J; Shenfield GM
Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
6. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
[TBL] [Abstract][Full Text] [Related]
8. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
10. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
[TBL] [Abstract][Full Text] [Related]
11. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
12. Oxidative polymorphism of debrisoquine in Parkinson's disease.
Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine oxidation polymorphism in a Tasmanian population.
Veronese ME; McLean S
Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
[TBL] [Abstract][Full Text] [Related]
14. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
15. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
[TBL] [Abstract][Full Text] [Related]
16. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
17. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
Pierce DM; Smith SE; Franklin RA
Eur J Clin Pharmacol; 1987; 33(1):59-65. PubMed ID: 3691597
[TBL] [Abstract][Full Text] [Related]
19. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS; Tucker GT; Woods HF
Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
[TBL] [Abstract][Full Text] [Related]
20. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
Al-Dabbagh SG; Idle JR; Smith RL
J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]